<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS104139</article-id><article-id pub-id-type="doi">10.1101/2020.11.12.379115</article-id><article-id pub-id-type="archive">PPR237580</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Neuraminidase inhibitors rewire neutrophil function <italic>in vivo</italic> in murine sepsis and <italic>ex vivo</italic> in COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>de Oliveira Formiga</surname><given-names>Rodrigo O.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Amaral</surname><given-names>Flávia C.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Camila F.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mendes</surname><given-names>Daniel A.G.B.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wanderley</surname><given-names>Carlos W.S.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lorenzini</surname><given-names>Cristina B.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Adara A.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Antônia</surname><given-names>Juliana</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Faria</surname><given-names>Lucas F.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Natale</surname><given-names>Caio C.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Paula</surname><given-names>Nicholas M.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Priscila C.S.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fonseca</surname><given-names>Fernanda R.</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Aires</surname><given-names>Luan</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Heck</surname><given-names>Nicoli</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Starick</surname><given-names>Márick R.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Queiroz-Junior</surname><given-names>Celso M.</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Felipe R.S.</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>de Souza</surname><given-names>Filipe R.O.</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Vivian V.</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Barroso</surname><given-names>Shana P.C.</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Morrot</surname><given-names>Alexandre</given-names></name><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Van Weyenbergh</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Sordi</surname><given-names>Regina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Alisson-Silva</surname><given-names>Frederico</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Cunha</surname><given-names>Fernando Q.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rocha</surname><given-names>Edroaldo L.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chollet-Martin</surname><given-names>Sylvie</given-names></name><xref ref-type="aff" rid="A13">13</xref></contrib><contrib contrib-type="author"><name><surname>Hurtado-Nedelec</surname><given-names>Maria Margarita</given-names></name><xref ref-type="aff" rid="A14">14</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Clémance</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Burgel</surname><given-names>Pierre-Régis</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A15">15</xref></contrib><contrib contrib-type="author"><name><surname>Mansur</surname><given-names>Daniel S.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maurici</surname><given-names>Rosemeri</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Macauley</surname><given-names>Matthew S.</given-names></name><xref ref-type="aff" rid="A16">16</xref></contrib><contrib contrib-type="author"><name><surname>Báfica</surname><given-names>André</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Witko-Sarsat</surname><given-names>Véronique</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spiller</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil</aff><aff id="A2"><label>2</label>Université de Paris, Institut Cochin, INSERM U1016, CNRS, Paris, France</aff><aff id="A3"><label>3</label>Laboratory of Immunobiology, Federal University of Santa Catarina (UFSC), Florianopolis, Santa Catarina, Brazil</aff><aff id="A4"><label>4</label>Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil</aff><aff id="A5"><label>5</label>Department of Clinical Medicine, Federal University of Santa Catarina (UFSC), Florianopolis, Santa Catarina, Brazil</aff><aff id="A6"><label>6</label>Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil</aff><aff id="A7"><label>7</label>Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil</aff><aff id="A8"><label>8</label>Molecular Biology Laboratory, Institute of Biomedical Research, Marcilio Dias Naval Hospital, Navy of Brazil, Rio de Janeiro, Brazil</aff><aff id="A9"><label>9</label>Tuberculosis Research Laboratory, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Immunoparasitology Laboratory, Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil</aff><aff id="A10"><label>10</label>Immunoparasitology Laboratory, Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil</aff><aff id="A11"><label>11</label>Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory for Clinical and Epidemiological Virology, KU Leuven, Leuven, Belgium</aff><aff id="A12"><label>12</label>Department of Immunology, Paulo de Goes Institute of Microbiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil</aff><aff id="A13"><label>13</label>INSERM UMR 996, “Infammation, Microbiome and Immunosurveillance”, Faculty of Pharmacy, Université Paris-Saclay, Châtenay-Malabry, France</aff><aff id="A14"><label>14</label>INSERM-U1149, Faculté de Médecine, Site Xavier Bichat, CNRS, Université de Paris, Paris, France</aff><aff id="A15"><label>15</label>Department of Pneumology, AP-HP, Hôpital Cochin, F-75014 PARIS-France</aff><aff id="A16"><label>16</label>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author: Fernando Spiller, Department of Pharmacology (FMC/CCB/UFSC), Av. Prof. Henrique da Silva Fontes, 321 - Trindade, Florianópolis – SC, 88040-900, Tel.: +55-48-3721-4852. <email>fernando.spiller@ufsc.br</email>, <email>spiller.farmaco@gmail.com</email>.</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="preprint"><day>12</day><month>11</month><year>2020</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license><license><ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref><license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p></license></permissions><abstract><p id="P1">Neutrophil overstimulation plays a crucial role in tissue damage during severe infections. Neuraminidase (NEU)-mediated cleavage of surface sialic acid has been demonstrated to regulate leukocyte responses. Here, we report that antiviral NEU inhibitors constrain host NEU activity, surface sialic acid release, ROS production, and NETs released by microbial-activated human neutrophils. <italic>In vivo</italic>, treatment with Oseltamivir results in infection control and host survival in peritonitis and pneumonia models of sepsis. Single-cell RNA sequencing re-analysis of publicly data sets of respiratory tract samples from critical COVID-19 patients revealed an overexpression of NEU1 in infiltrated neutrophils. Moreover, Oseltamivir or Zanamivir treatment of whole blood cells from severe COVID-19 patients reduces host NEU-mediated shedding of cell surface sialic acid and neutrophil overactivation. These findings suggest that neuraminidase inhibitors can serve as host-directed interventions to dampen neutrophil dysfunction in severe infections.</p></abstract><kwd-group><kwd>neuraminidase</kwd><kwd>sialic acid</kwd><kwd>sepsis</kwd><kwd>Oseltamivir</kwd><kwd>Zanamivir</kwd><kwd>neutrophil</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Neutrophils are key components of the immune response against pathogens (<xref ref-type="bibr" rid="R1">1</xref>). However, during severe acute infections, such as sepsis and COVID-19, overactivated neutrophils infiltrate vital organs and release molecules including proteases, reactive oxygen species (ROS), and neutrophil extracellular traps (NETs) (<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R3">3</xref>). While such inflammatory mediators are essential to the control of infection, they can also damage healthy cells (<xref ref-type="bibr" rid="R4">4</xref>). Therefore, the function of neutrophils must be regulated to efficiently clear microorganisms with minimal detrimental effects to the host.</p><p id="P3">A number of mechanisms controlling neutrophil activation have been described (<xref ref-type="bibr" rid="R5">5</xref>). For instance, the contents of sialic acid (Sia) have been demonstrated to regulate leukocyte activation to microbial stimuli (<xref ref-type="bibr" rid="R6">6</xref>). The dense array of Sia present in the glycocalyx of all mammalian cells makes this monosaccharide a central molecule for many cellular processes including: cell-cell interactions, signal transduction, and transendothelial migration (<xref ref-type="bibr" rid="R7">7</xref>). Neuraminidases (NEUs) are enzymes found in both pathogens and mammalian hosts, which hydrolyze Sia residues linked to galactose, N-acetylgalactosamine or polySia residues on glycoconjugates, thereby regulating many physiological and pathological responses (<xref ref-type="bibr" rid="R8">8</xref>). In human neutrophils, shedding of surface Sia by microbial-derived NEUs leads to cellular activation, ROS production, and release of NETs (<xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R12">12</xref>). Additionally, it has been demonstrated that LPS induces membrane-associated NEU activation in murine or human macrophages and dendritic cells (<xref ref-type="bibr" rid="R13">13</xref>). Upon LPS binding to TLR4, NEU activity was shown to regulate NF-κB induction in macrophages, suggesting a role for this enzyme during cellular activation (<xref ref-type="bibr" rid="R13">13</xref>). Also, in Gram-negative experimental sepsis, leukocyte dysfunction is mediated by NEU activity and associated with exacerbated inflammatory response and high mortality rates (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>). As previous studies have demonstrated that pathogen-derived NEU stimulate neutrophils, (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R16">16</xref>), we investigated whether endogenous host NEUs can be targeted to regulate neutrophil dysfunction observed in severe infections.</p><p id="P4">Here, we have identified host NEU activation as a positive regulator of microbial-induced human neutrophil overactivation. Additionally, we have employed antiviral NEU inhibitors, Oseltamivir and Zanamivir, to explore this pathway and found that these drugs fine-tune the neutrophil dysfunction observed in sepsis and COVID-19. Together, our results show that NEU is a potential target for the control of neutrophil dysfunction and present Oseltamivir or Zanamivir as adjunctive therapy for severe infections.</p></sec><sec id="S2" sec-type="methods"><title>Methods</title><sec id="S3"><title>Human blood samples</title><p id="P5">Blood samples were collected from severe COVID-19 (n=6) or convalescent COVID-19 (n=8) patients (25 to 89 yr old) admitted in the ICU or Research Center on Asthma and Airway Inflammation at the UFSC University Hospital. Blood samples from sex-matched healthy donors were used as controls. The research protocol was approved by the Institutional Review Board of the UFSC (CAAE #82815718.2.0000.0121, #36944620.5.1001.0121).</p></sec><sec id="S4"><title>Evaluation of neutrophil response</title><p id="P6">Whole blood were incubated in the presence or absence of Oseltamivir (100 µM, Sigma-Aldrich), Zanamivir (30 µM, Sigma-Aldrich), LPS (1 µg/mL, <italic>E. coli</italic> 0127:b8, Sigma-Aldrich), LPS plus Oseltamivir or LPS plus Zanamivir. Total leukocytes were used to evaluate the effect of isolated neuraminidase from <italic>Clostridium perfringens</italic> (CpNEU) on neutrophils. Leukocytes were incubated in the presence or absence of CpNEU (10 mU, Sigma-Aldrich), CpNEU plus Oseltamivir or CpNEU plus Zanamivir. Next, neutrophil activation, phagocytosis, bacterial killing, ROS production and NETs release were evaluated.</p></sec><sec id="S5"><title>Mice</title><p id="P7">All animal procedures followed the ARRIVE guidelines and the international principles for laboratory animal studies (<xref ref-type="bibr" rid="R17">17</xref>). Protocols were approved by the Animal Use Ethics Committee of UFSC (CEUA #8278290818). C57BL/6 and Swiss mice were used for peritonitis- or pneumonia-induced severe sepsis. Mice were randomly pretreated and/or post treated by <italic>per oral</italic> (PO, 12/12 hr) with saline or Oseltamivir phosphate (10 mg/kg, Eurofarma, Brazil).</p><p id="P8">Additional details and methods are found in <xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref>.</p></sec></sec><sec id="S6" sec-type="results"><title>Results</title><sec id="S7"><title>LPS-induced surface Sia shedding in human neutrophils is mediated by NEU activity</title><p id="P9">As activated NEUs hydrolyze Sia residues linked to underlying galactose glycoconjugates (<xref ref-type="bibr" rid="R7">7</xref>), we estimate Sia levels on neutrophils after their activation. LPS treatment of whole blood from healthy donors significantly reduces the binding of <italic>Maackia amurensis</italic> II (MAL-II, a lectin that binds selectively to <italic>α</italic>2-3- over <italic>α</italic>2-6-linked Sia (<xref ref-type="bibr" rid="R18">18</xref>)) on neutrophils when compared to untreated cells (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 2A</xref>). Next, cells were stained with an Fc-chimera of Siglec-9, a sialic acid-binding protein that recognizes Sia in <italic>α</italic>2-3 and <italic>α</italic>2-6 linkages (<xref ref-type="bibr" rid="R19">19</xref>). Similarly, binding of Siglec-9-Fc (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 2B</xref>) is decreased on neutrophils treated with LPS, confirming a reduction of neutrophil Sia residues likely due to LPS-induced NEU activity in these cells. To test this hypothesis, we measured NEU activity in human leukocytes using the NEU substrate 4-MU-NANA (<xref ref-type="bibr" rid="R13">13</xref>) and validated the assay using CpNEU (<xref ref-type="fig" rid="F1">Fig. 1A-B</xref>). Both clinically available NEU inhibitors Oseltamivir and Zanamivir reduce CpNEU activity (<xref ref-type="fig" rid="F1">Fig. 1A-B</xref>). LPS-induced NEU activity on leukocytes was also significantly inhibited by Oseltamivir or Zanamivir (<xref ref-type="fig" rid="F1">Fig. 1C-D</xref>). Moreover, these NEU inhibitors prevent LPS- or CpNEU-mediated reduction of MAL-II (<xref ref-type="fig" rid="F1">Fig. 1E-F; K-L</xref>) or <italic>Sambucus nigra</italic> (SNA) binding (SNA, a lectin that binds selectively to <italic>α</italic>2-6- over <italic>α</italic>2-3-linked Sia) (<xref ref-type="fig" rid="F1">Fig. 1G-H; M-N</xref>). Desialylation unmasks galactose residues that are recognized by the lectin peanut agglutinin (PNA) (<xref ref-type="bibr" rid="R20">20</xref>). NEU inhibitors prevent LPS- or CpNEU-mediated the increase of the PNA binding on neutrophils surface (<xref ref-type="fig" rid="F1">Fig. 1I-J; O-P</xref>). Together, these results show that LPS-induced host NEU activity decreases Sia content on neutrophils, which can be inhibited by Oseltamivir and Zanamivir.</p></sec><sec id="S8"><title>LPS-induced phagocytosis and killing of <italic>E. coli</italic> is modulated by NEU activity</title><p id="P10">Bacteria uptake and killing are important functions of neutrophils (<xref ref-type="bibr" rid="R3">3</xref>). We next investigated whether host NEU regulates phagocytosis and killing of <italic>E. coli.</italic> Whole blood or total leukocytes from healthy donors were preincubated with LPS or CpNEU, respectively, and <italic>E. coli</italic> BioParticles® added to cells for 60 min. Ingested pHrodo <italic>E. coli</italic> by neutrophils were analyzed by flow cytometry. A significant increase in the MFI of unstimulated cells incubated with pHrodo <italic>E. coli</italic> was observed at 37 °C compared to cells at 4 °C (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 3</xref>). LPS (<xref ref-type="fig" rid="F2">Fig. 2A-C</xref>) or CpNEU, used as a positive control of NEU effects (<xref ref-type="fig" rid="F2">Fig. 2D-F</xref>), but not heat-inactivated CpNEU, significantly enhances phagocytosis of <italic>E. coli</italic>. Remarkably, these effects are inhibited by Zanamivir or Oseltamivir (<xref ref-type="fig" rid="F2">Fig. 2A-F</xref>), suggesting that LPS-enhanced phagocytosis involves a host NEU-dependent pathway. Similarly, pretreatment of cells with LPS or CpNEU increases both the number of cells with bacteria as well as the number of bacteria per cell (<xref ref-type="fig" rid="F2">Fig. 2G-J</xref>). These effects were also abolished when NEU inhibitors Oseltamivir and Zanamivir were added in the cell cultures (<xref ref-type="fig" rid="F2">Fig. 2G-J</xref>). Furthermore, LPS or CpNEU treatment enhances intracellular and extracellular killing of <italic>E. coli,</italic> which are also inhibited by Oseltamivir or Zanamivir (<xref ref-type="fig" rid="F2">Fig. 2K-L</xref>). These results suggest that NEU plays a critical role in LPS-upregulated phagocytosis and killing responses of neutrophils.</p></sec><sec id="S9"><title>NEU blockade prevents neutrophil activation</title><p id="P11">Shedding of cell surface Sia by mobilization of granule-associated NEU to the cell surface has been associated with neutrophil activation (<xref ref-type="bibr" rid="R21">21</xref>). Therefore, we analyzed surface expression of CD66b and CD62L, two markers of human neutrophil activation (<xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R24">24</xref>) and <italic>α</italic>2-3-Sia levels in LPS-exposed whole blood cultures. Both Oseltamivir and Zanamivir inhibit LPS-induced shedding of <italic>α</italic>2-3-Sia (<xref ref-type="fig" rid="F3">Fig. 3A,B</xref>) and CD62L (<xref ref-type="fig" rid="F3">Fig. 3D,E</xref>) or upregulation of CD66b (<xref ref-type="fig" rid="F3">Fig. 3G,H</xref>) on neutrophils. Similarly, MAL-II preincubation, which prevents hydrolysis of <italic>α</italic>2-3-Sia by NEU due to steric hindrance at the enzyme cleavage site (<xref ref-type="bibr" rid="R25">25</xref>), blocks LPS-induced neutrophil activation (<xref ref-type="fig" rid="F3">Fig. 3C,F,I</xref>). These data show that dampening NEU activity or blocking the hydrolysis of <italic>α</italic>2-3-Sia is sufficient to inhibit human neutrophil activation by LPS. Similar results were observed in soluble CpNEU-treated leukocytes (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 4</xref>). Next, we assessed whether NEU inhibitors influenced LPS-stimulated ROS production and release of NETs, key mediators of bacterial killing and tissue injury (<xref ref-type="bibr" rid="R26">26</xref>). Neutrophils primed with LPS and stimulated with PMA produce higher amounts of ROS when compared to unprimed cells (<xref ref-type="fig" rid="F3">Fig. 3J-L</xref>). Both Oseltamivir and Zanamivir inhibit ROS release to levels similar to unprimed cells. These results were also reproduced by the treatment of cells with CpNEU (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 5E-G</xref>). Furthermore, Oseltamivir or Zanamivir significantly inhibit LPS-induced NETs released by isolated neutrophils (<xref ref-type="fig" rid="F3">Fig. 3M</xref>). Together, these data indicate that microbial-induced host NEU activity regulates important neutrophil functions <italic>in vitro</italic>.</p></sec><sec id="S10"><title>Oseltamivir enhances survival rate of mice in clinically relevant models of sepsis</title><p id="P12">Exacerbated neutrophil responses such as increased ROS production, release of NET and degranulation are associated with tissue injury and organ dysfunction (<xref ref-type="bibr" rid="R27">27</xref>). By using Oseltamivir as a therapeutic tool, we next explored the involvement of NEU activity <italic>in vivo</italic> during experimental sepsis, a model of neutrophil dysfunction (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R28">28</xref>, <xref ref-type="bibr" rid="R29">29</xref>). We first induced sepsis by intraperitoneal administration of 1 x 10<sup>7</sup> CFU/mice of the Gram-negative <italic>E. coli</italic> (ATCC 25922), which lacks NEU in its genome (<xref ref-type="bibr" rid="R30">30</xref>). We used a dose of 10 mg/Kg of Oseltamivir by oral gavage, which is the equivalent dose used in humans (∼7.5 mg/Kg) (<xref ref-type="bibr" rid="R31">31</xref>). Oseltamivir pretreatment (2 hr before infection) plus post-treatment (6 hr after infection, 12/12 h, PO, for 4 days) markedly boost host survival (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6A</xref>). Only a single dose of Oseltamivir 2 hr before bacterial administration significantly decreases the number of neutrophils in the BAL and lung tissue 4 or 6 hr after infection (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6B-C</xref>). This pretreatment also augments neutrophil migration to the focus of infection, which is associated with an efficient control of infection (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6D-F</xref>). Furthermore, pretreatment with Oseltamivir decreases BAL and plasma TNF and IL-17 levels (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6G-J</xref>) and tissue injury markers (AST, ALT, ALP and total bilirubin) (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6K-N</xref>), as well as prevents reduction of <italic>α</italic>2-3-Sia on peritoneal lavage SSC<sup>high</sup>/GR-1<sup>high</sup>cells (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6O-P</xref>). More importantly, the post-treatment efficacy of Oseltamivir was also evaluated in survival of septic mice. Mice were IP challenged with <italic>E. coli</italic> (1 x 10<sup>7</sup> CFU/mice) and treated 6 hr after infection with Oseltamivir for 4 days (10 mg/Kg, PO, 12/12h). Strikingly, in the post-treatment protocol, Oseltamivir provides a significant improvement in the survival rate of septic mice (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 6Q</xref>).</p><p id="P13">Next, we employed the CLP model to evaluate the effect of Oseltamivir in septic mice, as it is considered the gold standard in preclinical sepsis (<xref ref-type="bibr" rid="R32">32</xref>). Six hours after CLP, Oseltamivir post-treatment leads to a small delay in the mortality rate of severe septic mice (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 7A</xref>). Next, CLP septic mice were treated with antibiotics because it is one of the standard interventions used in clinical settings of sepsis (<xref ref-type="bibr" rid="R33">33</xref>). Importantly, compared to the control animals, therapeutic use of Oseltamivir plus antibiotics drastically improved survival rates of CLP mice (87.5% experimental group vs 25% control group) (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 7B</xref>). Forty-eight hr after surgery, post-treated septic mice have a significant reduction of neutrophils in BAL and lungs, improvement of neutrophil migration at the focus of infection, and reduced bacterial load in PL and blood (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 7C-G</xref>). Levels of TNF and IL-17 in PL and plasma and tissue injury markers were also reduced in Oseltamivir treated mice (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 7H-O</xref>). Additionally, Oseltamivir also leads to a higher expression of <italic>α</italic>2-3-Sia on SSC<sup>high</sup>/GR-1<sup>high</sup> cells in PL (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 7P-Q</xref>) confirming blockade of NEU activity <italic>in vivo</italic>.</p><p id="P14">As respiratory tract infections, particularly pneumonia, are among the most common sites of infection in sepsis (<xref ref-type="bibr" rid="R34">34</xref>), we intratracheally administered <italic>K. pneumoniae</italic> (ATCC 700603) into mice to address the effect of Oseltamivir. Post-treatment of mice with Oseltamivir significantly improves survival of septic mice challenged with <italic>K. pneumoniae</italic> (<xref ref-type="fig" rid="F4">FIG. 4A</xref>). The increased host survival was accompanied by a decrease of neutrophil migration in BAL, reduced levels of TNF and IL-17 and reduced levels of tissue injury markers (<xref ref-type="fig" rid="F4">Fig. 4B-K</xref>). Oseltamivir also prevents reduction of <italic>α</italic>2-3-Sia on BAL SSC<sup>high</sup>/GR-1<sup>high</sup> cells (<xref ref-type="fig" rid="F4">Fig. 4L-M</xref>). Together, these results show that host NEU activation exacerbates inflammatory responses during sepsis and the use of Oseltamivir improves disease outcome.</p></sec><sec id="S11"><title>Oseltamivir and Zanamivir rescue overactivated neutrophils from COVID-19 patients</title><p id="P15">Similar to bacterial sepsis, recent evidence suggests that neutrophils fuel hyper-inflammatory response during severe SARS-CoV-2 infection. Larger numbers of circulating neutrophils have been associated with poor prognosis of COVID-19 patients and analysis of lung biopsies and autopsy specimens showed extensive neutrophil infiltration (<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R35">35</xref>–<xref ref-type="bibr" rid="R41">41</xref>). Further studies by Chua <italic>et al.</italic> (2020) employing single-cell RNA sequencing (scRNA-seq) from upper and lower respiratory tract samples from COVID-19 patients indicated a significant augmentation of neutrophils linked to transcriptional program associated with tissue damage in epithelial and immune cells (<xref ref-type="bibr" rid="R42">42</xref>). Re-analysis of this scRNA-seq data (<xref ref-type="bibr" rid="R42">42</xref>) shows that expression of NEU1, but not NEU3 or NEU4, is upregulated in resident cells and highly expressed in neutrophils found in nasopharyngeal/pharyngeal swabs from COVID-19 patients (<xref ref-type="fig" rid="F5">Fig. 5</xref>). A similar profile of NEUs expression was also observed in lower respiratory tract samples from these patients (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 8</xref>). These results suggest NEU enzymes are highly (<xref ref-type="bibr" rid="R41">41</xref>) expressed by lung infiltrating neutrophils during severe COVID-19. As demonstrated by Schulte-Schrepping <italic>et al</italic>. (2020) (<xref ref-type="bibr" rid="R43">43</xref>), circulating neutrophils are highly activated on active, but not convalescent, COVID-19 patients as observed by CD62L shedding (<xref ref-type="fig" rid="F6">Fig. 6A</xref>) and upregulation of CD66b (<xref ref-type="fig" rid="F6">Fig. 6B</xref>). Moreover, neutrophils from severe COVID-19 patients were found to present a significant reduction of surface <italic>α</italic>2-3-Sia (<xref ref-type="fig" rid="F6">Fig. 6C,D</xref>), suggesting that NEU activity is also increased in blood neutrophils during severe COVID-19. Therefore, we asked whether neuraminidase inhibitors can rescue neutrophil activation from COVID-19 patients. <italic>Ex vivo</italic> treatment of whole blood with Oseltamivir or Zanamivir decreased neutrophil activation and restored the levels of cell surface sialic acid (<xref ref-type="fig" rid="F6">Fig. 6E-I</xref>). As soluble NEU enzymes are also present in plasma (<xref ref-type="bibr" rid="R14">14</xref>), we next asked if plasma from COVID-19 patients can induce neutrophil response from healthy donors. Indeed, stimulation of whole blood from healthy donors with fresh plasma from severe, but not convalescent, COVID-19 patients leads to neutrophil activation (<xref ref-type="fig" rid="F6">Fig. 6J</xref>), reduction of <italic>α</italic>2-3-Sia (<xref ref-type="fig" rid="F6">Fig. 6K</xref>) as well as ROS production (<xref ref-type="fig" rid="F6">Fig. 6L,M</xref>), which were significantly reduced by Oseltamivir or Zanamivir (<xref ref-type="fig" rid="F6">Fig. 6J-M</xref>). Additionally, activity of NEU is increased in plasma from severe COVID-19 patients (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 9A</xref>). Plasma samples from severe COVID-19 patients that were heat-inactivated to inhibit soluble NEU activity (<xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 9B</xref>) still induces neutrophil activation (<xref ref-type="fig" rid="F6">Fig. 6J-M</xref>), suggesting that cellular NEU in conjunction with circulating factors mediate NEU-dependent neutrophil activation in severe COVID-19. These results highlight host NEU as a regulator of neutrophil activation in severe COVID-19 and suggest this pathway as a potential host-directed intervention target to rewire neutrophil responses during severe diseased.</p></sec></sec><sec id="S12" sec-type="discussion"><title>Discussion</title><p id="P16">Systemic inflammatory responses may lead to unsuitable neutrophil stimulation, which is associated with higher mortality rates in sepsis and sepsis-like diseases (<xref ref-type="bibr" rid="R44">44</xref>). Therefore, finding new therapeutic options to prevent neutrophil overstimulation while maintaining their microbicidal abilities is greatly needed. Based on the findings presented here, NEU inhibitors are promising drugs to fill this gap. We demonstrated that endogenous host NEUs mediate exacerbated inflammatory responses by primary neutrophils. Clinically used viral NEU inhibitors, Oseltamivir and Zanamivir, decrease human NEU activity and are effective in preventing LPS-induced neutrophil responses or to rescue overactivation of neutrophils from COVID-19 patients. In severe murine sepsis, therapeutic use of Oseltamivir fine-tunes neutrophil migration promoting bacterial clearance and high survival rates.</p><p id="P17">All of the four different isotypes of NEU described in mammals (NEU1, NEU2, NEU3 and NEU4) remove Sia from glycoproteins and glycolipids with specific substrate preferences (<xref ref-type="bibr" rid="R45">45</xref>). NEU1 cleaves preferentially <italic>α</italic>2-3-Sia and seems to be the most important isoenzyme in immune cells. NEU1 is a lysosomal enzyme but it is also present at the cell surface where it can regulate multiple receptors such as Fc gamma receptor (FcγR), insulin receptor, integrin β-4, and TLRs (<xref ref-type="bibr" rid="R46">46</xref>). While several stimuli were described to induce NEU activity including LPS (<xref ref-type="bibr" rid="R13">13</xref>), PMA, calcium ionophore A23187, fMLP (<xref ref-type="bibr" rid="R21">21</xref>), and IL-8 (<xref ref-type="bibr" rid="R47">47</xref>), how NEUs are activated is poorly understood. However, NEU1 activation involves formation of a multicomplex of enzymes that stabilizes NEU1 in its conformational active state (<xref ref-type="bibr" rid="R48">48</xref>). Interestingly, NEU1 was found to be associated with matrix metalloproteinase-9 (MMP9) at the surface of naive macrophages (<xref ref-type="bibr" rid="R49">49</xref>). LPS binding to TLR4 leads to activation of a G protein-coupled receptor (GPCR) via Gɑi subunit and MMP9 to induce NEU1 activity, which in turn removes <italic>α</italic>2-3-Sia from TLR4, allowing its dimerization and intracellular signaling (<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R49">49</xref>, <xref ref-type="bibr" rid="R50">50</xref>). Although we have not formally addressed whether the LPS-TLR4 pathway directly activates NEU function in human neutrophils, our results employing MAL-II preincubation suggest desialylation is required for LPS-mediated neutrophil responses. Thus, it is possible that NEU controls Sia levels in TLR4 molecules in human neutrophils as observed in macrophages and dendritic cells (<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R50">50</xref>).</p><p id="P18">The upstream involvement of NEU regulating LPS responses by neutrophils is in agreement with the previous demonstration that TLRs stimulate these cells independent of gene transcription (<xref ref-type="bibr" rid="R51">51</xref>). Together, our data suggests that NEU activation provides a fast response to enhance microbial-induced neutrophil functions. Thus, we speculate that this could be an evolutionary mechanism by which neutrophils quickly mobilize their microbicidal mediators against pathogens.</p><p id="P19">Sialic acid removal from the surface of neutrophils markedly changes their adhesiveness, chemotaxis, and migration (<xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R56">56</xref>–<xref ref-type="bibr" rid="R58">58</xref>). In peritonitis- or pneumonia-induced sepsis in mice, we observed that Oseltamivir prevented the massive neutrophil infiltration into bronchoalveolar spaces or lung tissues, suggesting that regulation of neutrophil migration by dampening NEU activity contributes to survival of septic mice. Interestingly, we observed a divergent effect of Oseltamivir on neutrophil migration to the focus of infection between peritonitis- and pneumonia-induced sepsis. This could be explained by the different mechanisms involved in neutrophil migration to the peritoneal cavity and lungs. While expression of CD62L and rolling of neutrophils to endothelium is necessary for its migration to the peritoneal cavity, it seems to be not required for migration into the lungs (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R59">59</xref>). Moreover, systemic neutrophil activation leads to cell stiffening, resulting in retention of neutrophils in the small capillaries of the lungs (<xref ref-type="bibr" rid="R60">60</xref>), which is frequently the first organ impaired in non-pneumonia- and pneumonia-induced sepsis (<xref ref-type="bibr" rid="R61">61</xref>).</p><p id="P20">The role of NEU-induced neutrophil activation suggested here agrees with previous demonstration that NEU1 deletion in hematopoietic cells confers resistance to endotoxemia (<xref ref-type="bibr" rid="R15">15</xref>). Also, the sialidase inhibitor Neu5Gc2en protects endotoxemic irradiated wild-type (WT) mice reconstituted with WT bone marrow but not WT mice reconstituted with NEU1<sup>-/-</sup> bone marrow cells (<xref ref-type="bibr" rid="R15">15</xref>). Similar to our findings, the treatment of mice with NEU inhibitors increases host survival in <italic>E. coli</italic>-induced sepsis (<xref ref-type="bibr" rid="R14">14</xref>). This outcome was correlated with significant inhibition of blood NEU activity. Enhancement of soluble NEU activity in serum decreases the Sia residues from alkaline phosphatase (APL) enzymes, which are involved in the clearance of circulating LPS-phosphate during sepsis (<xref ref-type="bibr" rid="R14">14</xref>).</p><p id="P21">SARS-CoV-2 infection leads to mild illness in most of the patients, but ∼20% of them progress to severe disease with many characteristics resembling sepsis, including acute respiratory distress syndrome (ARDS), cytokine storm, and neutrophil dysregulation (<xref ref-type="bibr" rid="R38">38</xref>, <xref ref-type="bibr" rid="R62">62</xref>–<xref ref-type="bibr" rid="R64">64</xref>). The transcriptional programs found in neutrophil subsets from blood and lungs of severe COVID-19 patients are related to cell dysfunction, coagulation, and NETs formation (<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R43">43</xref>). We observed that blood neutrophils from severe COVID-19 are highly activated as demonstrated by reduced CD62L expression and increase of CD66b expression, as previously reported (<xref ref-type="bibr" rid="R43">43</xref>). We now add new information by showing that NEU1 is highly expressed in the respiratory tract of moderate and critical COVID-19 patients and blood neutrophils from severe, but not convalescent, COVID-19 patients with reduced surface levels of <italic>α</italic>2-3 and <italic>α</italic>2-6-Sia, suggesting a relevant role of NEU for COVID-19 pathology. More importantly, both the NEU inhibitors Oseltamivir and Zanamivir, increased the sialic acid content and rewired the overactivation of neutrophils from severe COVID-19 patients. We speculate that the addition of NEUs competitive inhibitors allowed the endogenous sialyltransferases to restore sialyl residues on surface glycoconjugates. Fast changes of surface sialic acid levels by sialidases and sialyltransferases seems to be an important mechanism to control neutrophil response (<xref ref-type="bibr" rid="R56">56</xref>). In neutrophils from healthy donors or COVID-19 convalescent patients, Oseltamivir and Zanamivir did not interfere in resting state and had no effect on sialic acid content, suggesting that NEU has a low effect on surface Sia turnover on non-activated neutrophils. How neutrophils are activated and the role of NEU in this process remains to be defined in COVID-19, nevertheless, recent evidence showed that neutrophils could be directly activated by SARS-CoV-2 (2), cytokines (<xref ref-type="bibr" rid="R65">65</xref>) and alarmins (<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R43">43</xref>), such as calprotectin (<xref ref-type="bibr" rid="R39">39</xref>), a TLR4 ligand (<xref ref-type="bibr" rid="R66">66</xref>). Furthermore, we now suggest that soluble NEU with other circulating factors present in plasma from severe COVID-19 patients also accounts for neutrophil activation.</p><p id="P22">Collectively, this work suggests that host NEU activation leads to shedding of surface sialic acid with consequent neutrophil overstimulation, tissue damage, and high mortality rates. On the other hand, NEU inhibitors-prevented shedding of sialic acid and regulates neutrophil response, resulting in infection control and high survival rates (working model in <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 10</xref>). Considering that both drugs have a safety profile with few well-known adverse effects, our data suggest Oseltamivir and Zanamivir could be repurposed for the treatment of sepsis or severe infections such as COVID-19. Interestingly, a retrospective single-center cohort study including 1190 patients with COVID-19 in Wuhan, China, showed that administration of Oseltamivir was associated with a decreased risk of death in severe patients (<xref ref-type="bibr" rid="R67">67</xref>). Nevertheless, randomized clinical trials with NEU inhibitors in sepsis and COVID-19 are required to directly explore this hypothesis.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplem methods and refererences</label><media xlink:href="EMS104139-supplement-Supplem_methods_and_refererences.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d2aAdEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplementary Material</label><media xlink:href="EMS104139-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d2aAdEcB" position="anchor"/></supplementary-material></sec></body><back><ack id="S13"><title>Acknowledgments</title><p>We thank Universidade Federal de Santa Catarina (UFSC), the Laboratório Multiusuário de Estudos em Biologia (LAMEB/UFSC), CAPES/PrInt, CNPq and Le programme de bourses d’excellence Eiffel (Campus France - Ministère de l’Europe et des Affaires étrangères) for the support.</p><sec id="S14"><title>Funding</title><p>This work was funded by FAPESP-SCRIPPS (FS; 15/50387-4), Howard Hughes Medical Institute – Early Career Scientist (AB; 55007412), National Institutes of Health Global Research Initiative Program (AB; TW008276), FWO (grant G0D6817N), CAPES Computational Biology (DSM; 23038.010048/2013–27), CNPQ/COVID-19 (AB; 401209/2020-2), CNPQ/PQ Scholars (AB and DSM), CAPES/PrINT, Le programme de bourses d’excellence Eiffel and FAPESC Scholarship (DM).</p></sec></ack><fn-group><fn fn-type="con" id="FN1"><p id="P23"><bold>Authors’ contributions</bold></p><p id="P24">All named authors meet the general criteria for authorship of this manuscript, take responsibility for the work’s integrity as a whole, and have given final approval for publication.</p><p id="P25">ROF, FCA, DM, RS, DSM, JVW, ELR, VWS, AB, MSM and FS designed experiments and analyzed data; ROF, FAC, CFS, DM, CWW, CLB, AAS, JA, LFF, CCN, NMP, PCS, FRF, FAS, LA, NH, AB and FS performed experiments; SB, AM, JVW, VWS, PRB, CM, ELR, MSM, FQC and RM contributed with critical reagents/tools/clinical samples; ROF, FS, AB wrote the manuscript.</p></fn><fn id="FN2" fn-type="conflict"><p id="P26"><bold>Competing Interests statement</bold></p><p id="P27">The authors declare that no conflict of interest exists.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mócsai</surname><given-names>A</given-names></name></person-group><article-title>Diverse novel functions of neutrophils in immunity, inflammation, and beyond</article-title><source>J Exp Med</source><year>2013</year><volume>210</volume><fpage>1283</fpage><lpage>1299</lpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veras</surname><given-names>FP</given-names></name><name><surname>Pontelli</surname><given-names>MC</given-names></name><name><surname>Silva</surname><given-names>CM</given-names></name><name><surname>Toller-Kawahisa</surname><given-names>JE</given-names></name><name><surname>de Lima</surname><given-names>M</given-names></name><name><surname>Nascimento</surname><given-names>DC</given-names></name><name><surname>Schneider</surname><given-names>AH</given-names></name><name><surname>Caetité</surname><given-names>D</given-names></name><name><surname>Tavares</surname><given-names>LA</given-names></name><name><surname>Paiva</surname><given-names>IM</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><etal/></person-group><article-title>SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology</article-title><source>J Exp Med</source><year>2020</year><volume>217</volume></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Spiller</surname><given-names>F</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name></person-group><article-title>Neutrophil paralysis in sepsis</article-title><source>Shock</source><year>2010</year><volume>34</volume><issue>Suppl 1</issue><fpage>15</fpage><lpage>21</lpage></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>AW</given-names></name></person-group><article-title>HOW NEUTROPHILS KILL MICROBES</article-title><source>Annual Review of Immunology</source><year>2005</year></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steevels</surname><given-names>TAM</given-names></name><name><surname>Meyaard</surname><given-names>L</given-names></name></person-group><article-title>Immune inhibitory receptors: essential regulators of phagocyte function</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><fpage>575</fpage><lpage>587</lpage></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macauley</surname><given-names>MS</given-names></name><name><surname>Crocker</surname><given-names>PR</given-names></name><name><surname>Paulson</surname><given-names>JC</given-names></name></person-group><article-title>Siglec-mediated regulation of immune cell function in disease</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>14</volume><fpage>653</fpage><lpage>666</lpage></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varki</surname><given-names>A</given-names></name></person-group><article-title>Sialic acids in human health and disease</article-title><source>Trends in Molecular Medicine</source><year>2008</year></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipničanová</surname><given-names>S</given-names></name><name><surname>Chmelová</surname><given-names>D</given-names></name><name><surname>Ondrejovič</surname><given-names>M</given-names></name><name><surname>Frecer</surname><given-names>V</given-names></name><name><surname>Miertuš</surname><given-names>S</given-names></name></person-group><article-title>Diversity of sialidases found in the human body - A review</article-title><source>Int J Biol Macromol</source><year>2020</year><volume>148</volume><fpage>857</fpage><lpage>868</lpage></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y-C</given-names></name><name><surname>Uchiyama</surname><given-names>S</given-names></name><name><surname>Varki</surname><given-names>A</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name></person-group><article-title>Leukocyte inflammatory responses provoked by pneumococcal sialidase</article-title><source>MBio</source><year>2012</year><volume>3</volume></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Kurita</surname><given-names>T</given-names></name><name><surname>Kakinuma</surname><given-names>K</given-names></name></person-group><article-title>Effects of neuraminidase on O2 consumption and release of O2 and H2O2 from phagocytosing human polymorphonuclear leukocytes</article-title><source>Blood</source><year>1982</year><volume>60</volume><fpage>446</fpage><lpage>453</lpage></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>DJ</given-names></name><name><surname>Henrichon</surname><given-names>M</given-names></name></person-group><article-title>Superoxide anion production in influenza protein-activated NADPH oxidase of human polymorphonuclear leukocytes</article-title><source>J Infect Dis</source><year>1994</year><volume>169</volume><fpage>1129</fpage><lpage>1133</lpage></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henricks</surname><given-names>PA</given-names></name><name><surname>van Erne-van der Tol</surname><given-names>ME</given-names></name><name><surname>Verhoef</surname><given-names>J</given-names></name></person-group><article-title>Partial removal of sialic acid enhances phagocytosis and the generation of superoxide and chemiluminescence by polymorphonuclear leukocytes</article-title><source>J Immunol</source><year>1982</year><volume>129</volume><fpage>745</fpage><lpage>750</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amith</surname><given-names>SR</given-names></name><name><surname>Jayanth</surname><given-names>P</given-names></name><name><surname>Franchuk</surname><given-names>S</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Seyrantepe</surname><given-names>V</given-names></name><name><surname>Gee</surname><given-names>K</given-names></name><name><surname>Basta</surname><given-names>S</given-names></name><name><surname>Beyaert</surname><given-names>R</given-names></name><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name><name><surname>Szewczuk</surname><given-names>MR</given-names></name></person-group><article-title>Dependence of pathogen molecule-induced toll-like receptor activation and cell function on Neu1 sialidase</article-title><source>Glycoconj J</source><year>2009</year><volume>26</volume><fpage>1197</fpage><lpage>1212</lpage></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Heithoff</surname><given-names>DM</given-names></name><name><surname>Aziz</surname><given-names>PV</given-names></name><name><surname>Haslund-Gourley</surname><given-names>B</given-names></name><name><surname>Westman</surname><given-names>JS</given-names></name><name><surname>Narisawa</surname><given-names>S</given-names></name><name><surname>Pinkerton</surname><given-names>AB</given-names></name><name><surname>Millán</surname><given-names>JL</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Mahan</surname><given-names>MJ</given-names></name><name><surname>Marth</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Accelerated Aging and Clearance of Host Anti-inflammatory Enzymes by Discrete Pathogens Fuels Sepsis</article-title><source>Cell Host Microbe</source><year>2018</year><volume>24</volume><fpage>500</fpage><lpage>513</lpage><elocation-id>e5</elocation-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G-Y</given-names></name><name><surname>Brown</surname><given-names>NK</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Khedri</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>van de Vlekkert</surname><given-names>D</given-names></name><name><surname>D’Azzo</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1</article-title><source>Elife</source><year>2014</year><volume>3</volume><elocation-id>e04066</elocation-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EL</given-names></name><name><surname>Debets-Ossenkopp</surname><given-names>Y</given-names></name><name><surname>Verbrugh</surname><given-names>HA</given-names></name><name><surname>Verhoef</surname><given-names>J</given-names></name></person-group><article-title>Initiation of the respiratory burst of human neutrophils by influenza virus</article-title><source>Infection and Immunity</source><year>1981</year></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilkenny</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research</article-title><source>Osteoarthritis Cartilage</source><year>2012</year><volume>20</volume><fpage>256</fpage><lpage>260</lpage></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knibbs</surname><given-names>RN</given-names></name><name><surname>Goldstein</surname><given-names>IJ</given-names></name><name><surname>Ratcliffe</surname><given-names>RM</given-names></name><name><surname>Shibuya</surname><given-names>N</given-names></name></person-group><article-title>Characterization of the carbohydrate binding specificity of the leukoagglutinating lectin from Maackia amurensis. Comparison with other sialic acid-specific lectins</article-title><source>Journal of Biological Chemistry</source><year>1991</year></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movsisyan</surname><given-names>LD</given-names></name><name><surname>Macauley</surname><given-names>MS</given-names></name></person-group><article-title>Structural advances of Siglecs: insight into synthetic glycan ligands for immunomodulation</article-title><source>Org Biomol Chem</source><year>2020</year><volume>18</volume><fpage>5784</fpage><lpage>5797</lpage></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varki</surname><given-names>A</given-names></name><name><surname>Gagneux</surname><given-names>P</given-names></name></person-group><article-title>Multifarious roles of sialic acids in immunity</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1253</volume><fpage>16</fpage><lpage>36</lpage></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>AS</given-names></name><name><surname>Wright</surname><given-names>DG</given-names></name></person-group><article-title>Mobilization of sialidase from intracellular stores to the surface of human neutrophils and its role in stimulated adhesion responses of these cells</article-title><source>J Clin Invest</source><year>1991</year><volume>88</volume><fpage>2067</fpage><lpage>2076</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Zündorf</surname><given-names>J</given-names></name><name><surname>Grüger</surname><given-names>T</given-names></name><name><surname>Brandenburg</surname><given-names>K</given-names></name><name><surname>Reiners</surname><given-names>A-L</given-names></name><name><surname>Zinserling</surname><given-names>J</given-names></name><name><surname>Schnitzler</surname><given-names>N</given-names></name></person-group><article-title>CD66b overexpression and homotypic aggregation of human peripheral blood neutrophils after activation by a gram-positive stimulus</article-title><source>J Leukoc Biol</source><year>2012</year><volume>91</volume><fpage>791</fpage><lpage>802</lpage></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>TK</given-names></name><name><surname>Jutila</surname><given-names>MA</given-names></name><name><surname>Berg</surname><given-names>EL</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group><article-title>Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>1238</fpage><lpage>1241</lpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutila</surname><given-names>MA</given-names></name><name><surname>Rott</surname><given-names>L</given-names></name><name><surname>Berg</surname><given-names>EL</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name></person-group><article-title>Function and regulation of the neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1</article-title><source>J Immunol</source><year>1989</year><volume>143</volume><fpage>3318</fpage><lpage>3324</lpage></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amith</surname><given-names>SR</given-names></name><name><surname>Jayanth</surname><given-names>P</given-names></name><name><surname>Franchuk</surname><given-names>S</given-names></name><name><surname>Finlay</surname><given-names>T</given-names></name><name><surname>Seyrantepe</surname><given-names>V</given-names></name><name><surname>Beyaert</surname><given-names>R</given-names></name><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name><name><surname>Szewczuk</surname><given-names>MR</given-names></name></person-group><article-title>Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling</article-title><source>Cell Signal</source><year>2010</year><volume>22</volume><fpage>314</fpage><lpage>324</lpage></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>M</given-names></name><name><surname>Siddiqui</surname><given-names>MR</given-names></name><name><surname>Tran</surname><given-names>K</given-names></name><name><surname>Reddy</surname><given-names>SP</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name></person-group><article-title>Reactive oxygen species in inflammation and tissue injury</article-title><source>Antioxid Redox Signal</source><year>2014</year><volume>20</volume><fpage>1126</fpage><lpage>1167</lpage></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sônego</surname><given-names>F</given-names></name><name><surname>Castanheira</surname><given-names>FVES</given-names></name><name><surname>Ferreira</surname><given-names>RG</given-names></name><name><surname>Kanashiro</surname><given-names>A</given-names></name><name><surname>Leite</surname><given-names>CAVG</given-names></name><name><surname>Nascimento</surname><given-names>DC</given-names></name><name><surname>Colón</surname><given-names>DF</given-names></name><name><surname>Borges</surname><given-names>V de F</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name></person-group><article-title>Paradoxical Roles of the Neutrophil in Sepsis: Protective and Deleterious</article-title><source>Front Immunol</source><year>2016</year><volume>7</volume><fpage>155</fpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>F</given-names></name><name><surname>Orrico</surname><given-names>MIL</given-names></name><name><surname>Nascimento</surname><given-names>DC</given-names></name><name><surname>Czaikoski</surname><given-names>PG</given-names></name><name><surname>Souto</surname><given-names>FO</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Freitas</surname><given-names>A</given-names></name><name><surname>Carlos</surname><given-names>D</given-names></name><name><surname>Montenegro</surname><given-names>MF</given-names></name><name><surname>Neto</surname><given-names>AF</given-names></name><name><surname>Ferreira</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Hydrogen sulfide improves neutrophil migration and survival in sepsis via K+ATP channel activation</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>182</volume><fpage>360</fpage><lpage>368</lpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>F</given-names></name><name><surname>Carlos</surname><given-names>D</given-names></name><name><surname>Souto</surname><given-names>FO</given-names></name><name><surname>de Freitas</surname><given-names>A</given-names></name><name><surname>Soares</surname><given-names>FS</given-names></name><name><surname>Vieira</surname><given-names>SM</given-names></name><name><surname>Paula</surname><given-names>FJA</given-names></name><name><surname>Alves-Filho</surname><given-names>JC</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name></person-group><article-title>α1-Acid glycoprotein decreases neutrophil migration and increases susceptibility to sepsis in diabetic mice</article-title><source>Diabetes</source><year>2012</year><volume>61</volume><fpage>1584</fpage><lpage>1591</lpage></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vimr</surname><given-names>ER</given-names></name><name><surname>Troy</surname><given-names>FA</given-names></name></person-group><article-title>Identification of an inducible catabolic system for sialic acids (nan) in Escherichia coli</article-title><source>J Bacteriol</source><year>1985</year><volume>164</volume><fpage>845</fpage><lpage>853</lpage></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>CC</given-names></name><name><surname>van der Velden</surname><given-names>AW</given-names></name><name><surname>Bongard</surname><given-names>E</given-names></name><name><surname>Saville</surname><given-names>BR</given-names></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Coenen</surname><given-names>S</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name><name><surname>Francis</surname><given-names>NA</given-names></name><name><surname>Lewis</surname><given-names>RJ</given-names></name><name><surname>Godycki-Cwirko</surname><given-names>M</given-names></name><name><surname>Llor</surname><given-names>C</given-names></name><etal/></person-group><article-title>Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>42</fpage><lpage>52</lpage></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Huber-Lang</surname><given-names>MS</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group><article-title>Immunodesign of experimental sepsis by cecal ligation and puncture</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>31</fpage><lpage>36</lpage></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>LE</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Sevransky</surname><given-names>JE</given-names></name><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Nunnally</surname><given-names>ME</given-names></name><name><surname>Rochwerg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016</article-title><source>Intensive Care Med</source><year>2017</year><volume>43</volume><fpage>304</fpage><lpage>377</lpage></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>EH</given-names></name><name><surname>Mann</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>T-C</given-names></name><name><surname>Hsu</surname><given-names>W-T</given-names></name><name><surname>Liu</surname><given-names>CC-Y</given-names></name><name><surname>Bhakta</surname><given-names>T</given-names></name><name><surname>Hassani</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>C-C</given-names></name></person-group><article-title>Incidence, trends, and outcomes of infection sites among hospitalizations of sepsis: A nationwide study</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><elocation-id>e0227752</elocation-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Middleton</surname><given-names>EA</given-names></name><name><surname>He</surname><given-names>X-Y</given-names></name><name><surname>Denorme</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>RA</given-names></name><name><surname>Ng</surname><given-names>D</given-names></name><name><surname>Salvatore</surname><given-names>SP</given-names></name><name><surname>Mostyka</surname><given-names>M</given-names></name><name><surname>Baxter-Stoltzfus</surname><given-names>A</given-names></name><name><surname>Borczuk</surname><given-names>AC</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Cody</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</article-title><source>Blood</source><year>2020</year><volume>136</volume><fpage>1169</fpage><lpage>1179</lpage></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schurink</surname><given-names>B</given-names></name><name><surname>Roos</surname><given-names>E</given-names></name><name><surname>Radonic</surname><given-names>T</given-names></name><name><surname>Barbe</surname><given-names>E</given-names></name><name><surname>Bouman</surname><given-names>CSC</given-names></name><name><surname>de Boer</surname><given-names>HH</given-names></name><name><surname>de Bree</surname><given-names>GJ</given-names></name><name><surname>Bulle</surname><given-names>EB</given-names></name><name><surname>Aronica</surname><given-names>EM</given-names></name><name><surname>Florquin</surname><given-names>S</given-names></name><name><surname>Fronczek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study</article-title><source>Lancet Microbe</source><year>2020</year><volume>1</volume><fpage>e290</fpage><lpage>e299</lpage></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W-J</given-names></name><name><surname>Ni</surname><given-names>Z-Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>W-H</given-names></name><name><surname>Ou</surname><given-names>C-Q</given-names></name><name><surname>He</surname><given-names>J-X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>C-L</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1708</fpage><lpage>1720</lpage></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvin</surname><given-names>A</given-names></name><name><surname>Chapuis</surname><given-names>N</given-names></name><name><surname>Dunsmore</surname><given-names>G</given-names></name><name><surname>Goubet</surname><given-names>A-G</given-names></name><name><surname>Dubuisson</surname><given-names>A</given-names></name><name><surname>Derosa</surname><given-names>L</given-names></name><name><surname>Almire</surname><given-names>C</given-names></name><name><surname>Hénon</surname><given-names>C</given-names></name><name><surname>Kosmider</surname><given-names>O</given-names></name><name><surname>Droin</surname><given-names>N</given-names></name><name><surname>Rameau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1401</fpage><lpage>1418</lpage><elocation-id>e18</elocation-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Rustagi</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>NQ</given-names></name><name><surname>Roque</surname><given-names>J</given-names></name><name><surname>Martínez-Colón</surname><given-names>GJ</given-names></name><name><surname>McKechnie</surname><given-names>JL</given-names></name><name><surname>Ivison</surname><given-names>GT</given-names></name><name><surname>Ranganath</surname><given-names>T</given-names></name><name><surname>Vergara</surname><given-names>R</given-names></name><name><surname>Hollis</surname><given-names>T</given-names></name><name><surname>Simpson</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>A single-cell atlas of the peripheral immune response in patients with severe COVID-19</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><fpage>1070</fpage><lpage>1076</lpage></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Rosenfeld</surname><given-names>AM</given-names></name><name><surname>Ittner</surname><given-names>CAG</given-names></name><name><surname>Weisman</surname><given-names>AR</given-names></name><name><surname>Agyekum</surname><given-names>RS</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Vella</surname><given-names>LA</given-names></name><name><surname>Kuthuru</surname><given-names>O</given-names></name><etal/></person-group><article-title>Comprehensive mapping of immune perturbations associated with severe COVID-19</article-title><source>Sci Immunol</source><year>2020</year><volume>5</volume></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>RL</given-names></name><name><surname>Lukassen</surname><given-names>S</given-names></name><name><surname>Trump</surname><given-names>S</given-names></name><name><surname>Hennig</surname><given-names>BP</given-names></name><name><surname>Wendisch</surname><given-names>D</given-names></name><name><surname>Pott</surname><given-names>F</given-names></name><name><surname>Debnath</surname><given-names>O</given-names></name><name><surname>Thürmann</surname><given-names>L</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Völker</surname><given-names>MT</given-names></name><name><surname>Kazmierski</surname><given-names>J</given-names></name><etal/></person-group><article-title>COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis</article-title><source>Nat Biotechnol</source><year>2020</year><volume>38</volume><fpage>970</fpage><lpage>979</lpage></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Reusch</surname><given-names>N</given-names></name><name><surname>Paclik</surname><given-names>D</given-names></name><name><surname>Baßler</surname><given-names>K</given-names></name><name><surname>Schlickeiser</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Krämer</surname><given-names>B</given-names></name><name><surname>Krammer</surname><given-names>T</given-names></name><name><surname>Brumhard</surname><given-names>S</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>De Domenico</surname><given-names>E</given-names></name><etal/></person-group><article-title>Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1419</fpage><lpage>1440</lpage><elocation-id>e23</elocation-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leliefeld</surname><given-names>PHC</given-names></name><name><surname>Wessels</surname><given-names>CM</given-names></name><name><surname>Leenen</surname><given-names>LPH</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Pillay</surname><given-names>J</given-names></name></person-group><article-title>The role of neutrophils in immune dysfunction during severe inflammation</article-title><source>Crit Care</source><year>2016</year><volume>20</volume><fpage>73</fpage></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smutova</surname><given-names>V</given-names></name><name><surname>Albohy</surname><given-names>A</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Korchagina</surname><given-names>E</given-names></name><name><surname>Miyagi</surname><given-names>T</given-names></name><name><surname>Bovin</surname><given-names>N</given-names></name><name><surname>Cairo</surname><given-names>CW</given-names></name><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name></person-group><article-title>Structural basis for substrate specificity of mammalian neuraminidases</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><elocation-id>e106320</elocation-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glanz</surname><given-names>VY</given-names></name><name><surname>Myasoedova</surname><given-names>VA</given-names></name><name><surname>Grechko</surname><given-names>AV</given-names></name><name><surname>Orekhov</surname><given-names>AN</given-names></name></person-group><article-title>Sialidase activity in human pathologies</article-title><source>Eur J Pharmacol</source><year>2019</year><volume>842</volume><fpage>345</fpage><lpage>350</lpage></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>AS</given-names></name><name><surname>Sakarya</surname><given-names>S</given-names></name><name><surname>Rifat</surname><given-names>S</given-names></name><name><surname>Held</surname><given-names>TK</given-names></name><name><surname>Drysdale</surname><given-names>B-E</given-names></name><name><surname>Grange</surname><given-names>PA</given-names></name><name><surname>Cassels</surname><given-names>FJ</given-names></name><name><surname>Wang</surname><given-names>L-X</given-names></name><name><surname>Stamatos</surname><given-names>N</given-names></name><name><surname>Farese</surname><given-names>A</given-names></name><name><surname>Casey</surname><given-names>D</given-names></name><etal/></person-group><article-title>Recruitment of murine neutrophils in vivo through endogenous sialidase activity</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>4112</fpage><lpage>4120</lpage></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name><name><surname>Hinek</surname><given-names>A</given-names></name></person-group><article-title>Where catabolism meets signalling: neuraminidase 1 as a modulator of cell receptors</article-title><source>Glycoconj J</source><year>2011</year><volume>28</volume><fpage>441</fpage><lpage>452</lpage></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulkhalek</surname><given-names>S</given-names></name><name><surname>Amith</surname><given-names>SR</given-names></name><name><surname>Franchuk</surname><given-names>SL</given-names></name><name><surname>Jayanth</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Finlay</surname><given-names>T</given-names></name><name><surname>Gilmour</surname><given-names>A</given-names></name><name><surname>Guzzo</surname><given-names>C</given-names></name><name><surname>Gee</surname><given-names>K</given-names></name><name><surname>Beyaert</surname><given-names>R</given-names></name><name><surname>Szewczuk</surname><given-names>MR</given-names></name></person-group><article-title>Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for Toll-like receptor activation and cellular signaling</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>36532</fpage><lpage>36549</lpage></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Stamatos</surname><given-names>NM</given-names></name><name><surname>Dragan</surname><given-names>AI</given-names></name><name><surname>Medvedev</surname><given-names>A</given-names></name><name><surname>Whitford</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Rallabhandi</surname><given-names>P</given-names></name><name><surname>Cole</surname><given-names>L</given-names></name><name><surname>Nhu</surname><given-names>QM</given-names></name><name><surname>Vogel</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Sialyl residues modulate LPS-mediated signaling through the Toll-like receptor 4 complex</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><elocation-id>e32359</elocation-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blander</surname><given-names>JM</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><article-title>Regulation of phagosome maturation by signals from toll-like receptors</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1014</fpage><lpage>1018</lpage></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>SE</given-names></name><name><surname>O’Connell</surname><given-names>RM</given-names></name><name><surname>Miranda</surname><given-names>GA</given-names></name><name><surname>Vaidya</surname><given-names>SA</given-names></name><name><surname>Chow</surname><given-names>EK</given-names></name><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name><name><surname>Yeh</surname><given-names>W-C</given-names></name><name><surname>Lane</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Toll-like Receptors Induce a Phagocytic Gene Program through p38</article-title><source>Journal of Experimental Medicine</source><year>2004</year></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Benna</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>PM-C</given-names></name><name><surname>Gougerot-Pocidalo</surname><given-names>M-A</given-names></name></person-group><article-title>Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane</article-title><source>Semin Immunopathol</source><year>2008</year><volume>30</volume><fpage>279</fpage><lpage>289</lpage></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkmann</surname><given-names>V</given-names></name></person-group><article-title>Neutrophil Extracellular Traps Kill Bacteria</article-title><source>Science</source><year>2004</year></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böhmer</surname><given-names>RH</given-names></name><name><surname>Trinkle</surname><given-names>LS</given-names></name><name><surname>Staneck</surname><given-names>JL</given-names></name></person-group><article-title>Dose effects of LPS on neutrophils- in a whole blood flow cytometric assay of phagocytosis and oxidative burst</article-title><source>Cytometry</source><year>1992</year></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rifat</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>TJ</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Puche</surname><given-names>AC</given-names></name><name><surname>Stamatos</surname><given-names>NM</given-names></name><name><surname>Goldblum</surname><given-names>SE</given-names></name><name><surname>Brossmer</surname><given-names>R</given-names></name><name><surname>Cross</surname><given-names>AS</given-names></name></person-group><article-title>Expression of sialyltransferase activity on intact human neutrophils</article-title><source>J Leukoc Biol</source><year>2008</year><volume>84</volume><fpage>1075</fpage><lpage>1081</lpage></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Almulki</surname><given-names>L</given-names></name><name><surname>Faez</surname><given-names>S</given-names></name><name><surname>Whitford</surname><given-names>M</given-names></name><name><surname>Hafezi-Moghadam</surname><given-names>A</given-names></name><name><surname>Cross</surname><given-names>AS</given-names></name></person-group><article-title>Endogenous PMN sialidase activity exposes activation epitope on CD11b/CD18 which enhances its binding interaction with ICAM-1</article-title><source>J Leukoc Biol</source><year>2011</year><volume>90</volume><fpage>313</fpage><lpage>321</lpage></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakarya</surname><given-names>S</given-names></name><name><surname>Rifat</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Bannerman</surname><given-names>DD</given-names></name><name><surname>Stamatos</surname><given-names>NM</given-names></name><name><surname>Cross</surname><given-names>AS</given-names></name><name><surname>Goldblum</surname><given-names>SE</given-names></name></person-group><article-title>Mobilization of neutrophil sialidase activity desialylates the pulmonary vascular endothelial surface and increases resting neutrophil adhesion to and migration across the endothelium</article-title><source>Glycobiology</source><year>2004</year><volume>14</volume><fpage>481</fpage><lpage>494</lpage></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>B</given-names></name><name><surname>Phillipson</surname><given-names>M</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><article-title>The physiology of leukocyte recruitment: an in vivo perspective</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>6439</fpage><lpage>6446</lpage></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worthen</surname><given-names>GS</given-names></name><name><surname>Schwab</surname><given-names>B</given-names><suffix>3rd</suffix></name><name><surname>Elson</surname><given-names>EL</given-names></name><name><surname>Downey</surname><given-names>GP</given-names></name></person-group><article-title>Mechanics of stimulated neutrophils: cell stiffening induces retention in capillaries</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>183</fpage><lpage>186</lpage></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>C-C</given-names></name><name><surname>Gong</surname><given-names>MN</given-names></name><name><surname>Zhai</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Bajwa</surname><given-names>EK</given-names></name><name><surname>Clardy</surname><given-names>PF</given-names></name><name><surname>Gallagher</surname><given-names>DC</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name></person-group><article-title>Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS</article-title><source>Chest</source><year>2010</year><volume>138</volume><fpage>559</fpage><lpage>567</lpage></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name></person-group><article-title>Comorbidities and multi-organ injuries in the treatment of COVID-19</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1239</fpage><lpage>1242</lpage></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hottz</surname><given-names>ED</given-names></name><name><surname>Azevedo-Quintanilha</surname><given-names>IG</given-names></name><name><surname>Palhinha</surname><given-names>L</given-names></name><name><surname>Teixeira</surname><given-names>L</given-names></name><name><surname>Barreto</surname><given-names>EA</given-names></name><name><surname>Pão</surname><given-names>CRR</given-names></name><name><surname>Righy</surname><given-names>C</given-names></name><name><surname>Franco</surname><given-names>S</given-names></name><name><surname>Souza</surname><given-names>TML</given-names></name><name><surname>Kurtz</surname><given-names>P</given-names></name><name><surname>Bozza</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19</article-title><source>Blood</source><year>2020</year><volume>136</volume><fpage>1330</fpage><lpage>1341</lpage></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Montaner</surname><given-names>LJ</given-names></name></person-group><article-title>Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts</article-title><source>J Leukoc Biol</source><year>2020</year><volume>108</volume><fpage>17</fpage><lpage>41</lpage></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogl</surname><given-names>T</given-names></name><name><surname>Stratis</surname><given-names>A</given-names></name><name><surname>Wixler</surname><given-names>V</given-names></name><name><surname>Völler</surname><given-names>T</given-names></name><name><surname>Thurainayagam</surname><given-names>S</given-names></name><name><surname>Jorch</surname><given-names>SK</given-names></name><name><surname>Zenker</surname><given-names>S</given-names></name><name><surname>Dreiling</surname><given-names>A</given-names></name><name><surname>Chakraborty</surname><given-names>D</given-names></name><name><surname>Fröhling</surname><given-names>M</given-names></name><name><surname>Paruzel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><fpage>1852</fpage><lpage>1866</lpage></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study</article-title><source>Ann Intensive Care</source><year>2020</year><volume>10</volume><fpage>99</fpage></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>At a Glance</title></caption><p>In a severe systemic inflammatory response, such as sepsis and COVID-19, neutrophils play a central role in organ damage. Thus, finding new ways to inhibit the exacerbated response of these cells is greatly needed. Here, we demonstrate that <italic>in vitro</italic> treatment of whole blood with the viral neuraminidase inhibitors Oseltamivir or Zanamivir, inhibits the activity of human neuraminidases as well as the exacerbated response of neutrophils. In experimental models of severe sepsis, oseltamivir decreased neutrophil activation and increased the survival rate of mice. Moreover, Oseltamivir or Zanamivir <italic>ex vivo</italic> treatment of whole blood cells from severe COVID-19 patients rewire neutrophil function.</p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>LPS stimulates NEU activity in human leukocytes.</title><p>Neuraminidase isolated from <italic>Clostridium perfringens</italic> (CpNEU) was used to validate the NEU activity assay. CpNEU (0.012 UI) was added in a 96-well flat-bottom dark plate on ice in the presence or absence of Oseltamivir phosphate (100 µM) or Zanamivir (30 µM). Next, the substrate 4-MU-NANA (0.025 mM) was added and the fluorescent substrate was read 3 min after at 37 °C (<bold>A</bold>). The area under the curve (AUC) values are shown in <bold>B</bold>. Total leukocytes resuspended in HBSS were added in a plate on ice and 4-MU-NANA substrate (0.025 mM) was added followed by the addition of medium, LPS (1 µg/mL), LPS plus Oseltamivir (100 µM) or LPS plus Zanamivir (30 µM). The fluorescent substrate was read 3 min after at 37 °C (<bold>C</bold>). Raw data were subtracted from the control group containing only HBSS (medium) and expressed as AUC values (<bold>D</bold>). Whole blood containing 1 x 10<sup>6</sup> leukocytes from healthy donors were stimulated or not with LPS (1 µg/mL, 90 min, 37 °C, 5% CO<sub>2</sub>), LPS plus Oseltamivir (100 µM), or LPS plus Zanamivir (30 µM). Total leukocytes (1 x 10<sup>6</sup>) were incubated with CpNEU (10 mU, 60 min, 37 °C, 5% CO<sub>2</sub>), CpNEU plus Oseltamivir (100 µM), or CpNEU plus Zanamivir (30 µM). Leukocytes were stained with MAL-II to detect <italic>α</italic>2-3 sialic acids (<bold>E-F; K-L</bold>), with SNA to detect <italic>α</italic>2-6 sialic acids (<bold>G-H; M-N</bold>) or PNA to detect galactosyl (β-1,3) N-acetylgalactosamine (<bold>I-J; O-P</bold>). The MFI was analyzed on CD66b<sup>+</sup>/CD15<sup>+</sup> cells using the gate strategies shown in <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 1</xref>. *<italic>P</italic>&lt; 0.05; **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.001. This figure is representative of three independent experiments (n= 3-6) and data are shown as mean ± SEM. LPS = lipopolysaccharide; CpNEU = neuraminidase; MAL-II = <italic>Maackia amurensis</italic> lectin II; SNA = <italic>Sambucus nigra</italic> lectin; PNA = peanut agglutinin.</p></caption><graphic xlink:href="EMS104139-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>LPS increases phagocytosis and killing of <italic>E. coli</italic> in a NEU-dependent manner.</title><p>Whole blood from healthy donors containing 1 x 10<sup>6</sup> leukocytes were exposed (37 °C, 5% CO<sub>2</sub>) or not to LPS (1 µg/mL, 90 min), LPS plus Oseltamivir (100 µM), or LPS plus Zanamivir (30 µM) (<bold>A-C; G-H; K</bold>). Total leukocytes (1 x 10<sup>6</sup>) were exposed or not to CpNEU (10 mU, 60 min, 37 °C, 5% CO<sub>2</sub>), CpNEU plus Oseltamivir (100 µM), or CpNEU plus Zanamivir (30 µM) (<bold>D-F; I-J; L</bold>) and the phagocytosis and killing assays were performed. Leukocytes were incubated with <italic>E. coli</italic> pHrodo BioParticles® (100 µg/mL) for 60 min at 37 °C to assess phagocytosis in viable CD66b<sup>+</sup>/CD15<sup>+</sup> cells (<bold>A-F</bold>) (as gated in <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 1</xref>). Live <italic>E. coli</italic> was used to evaluate phagocytosis by light microscopy or to assess the killing by leukocytes. Cells were stimulated as described above and 1 x10<sup>6</sup> leukocytes were incubated at 37 °C with <italic>E. coli</italic> (1 x10<sup>6</sup> CFU) for 90 min for phagocytosis or for 180 min for killing assays. The percentage of cells with ingested bacteria (<bold>G; I</bold>) and the number of bacterial particles per cell (<bold>H; J</bold>, <italic>≥</italic>3 particles per cell) were evaluated. The killing of <italic>E. coli</italic> was evaluated by spreading 10 µL of supernatant (extracellular killing) or 10 µL of the intracellular content in agar medium and the CFU were counted. Killing <italic>E. coli</italic> was expressed as the rate of fold change compared to the unprimed (untreated) cells (<bold>L</bold>). Symbols represent individual donors and data are shown as mean ± SEM from pooled data of two to three independent experiments (n = 3-12). *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="EMS104139-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>LPS-induced human neutrophil response involves NEU activity.</title><p>Whole blood from healthy donors containing 1 x 10<sup>6</sup> leukocytes were stimulated or not with LPS (1 µg/mL, 90 min, 37 °C, 5% CO<sub>2</sub>), LPS plus Oseltamivir (Osel, 100 µM), LPS plus Zanamivir (Zana, 30 µM), or LPS plus MAL-II (1 µg/mL, MAL-II promotes steric hindrance at the NEU cleavage site and prevent sialic acid cleavage). Leukocytes were marked with MAL-II (<bold>A-C</bold>) or with the cell activation markers CD62L (<bold>D-F</bold>) and CD66b (<bold>G-I</bold>). After red blood cells lysis leukocytes were incubated with 5 µM CM-H2DCFDA fluorescent probe for 15 min. PMA (10 µM) was used to stimulate ROS production for 10 min (<bold>J-L</bold>). <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 5</xref> showed ROS production in additional control groups. The MFI was analyzed on CD66b<sup>+</sup> cells using the gate strategies shown in <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 1</xref>. Isolated neutrophils were treated with Osetamivir (100 µM) or Zanamivir (30 µM) 1 h before the stimulus with LPS (10 µg/mL) for 4 h. The concentration of NETs was evaluated by MPO-DNA PicoGreen assay on supernatants of cells (<bold>M</bold>). Symbols represent individual donors and data are shown as mean ± SEM from pooled data of two to three independent experiments (n = 7) except for F and M that was made once with n=3. ***<italic>P</italic> &lt; 0.001; **<italic>P</italic> &lt; 0.01. CM-H2DCFDA = 5-(and-6)-chloromethyl-2’,7’- dichlorodihydrofluorescein diacetate, acetyl ester; PMA = phorbol 12-myristate 13- acetate; ROS = reactive oxygen species; NETs = neutrophil extracellular traps; PMN = polymorphonuclear leukocytes.</p></caption><graphic xlink:href="EMS104139-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Oseltamivir enhanced mice survival in <italic>K. pneumoniae</italic>-induced sepsis.</title><p>Sepsis was induced by intratracheal administration of <italic>K. pneumoniae</italic> and mice were randomly treated (starting 6 hr after infection, 12/12 hr, PO, n=20) with saline or Oseltamivir phosphate (10 mg/kg) and survival rates were monitored for 144 hr (<bold>A</bold>). In similar set of experiments, septic mice (n=6-7) were treated 6 hr after infection with a single dose of Oseltamivir phosphate (10 mg/kg, PO) and mice were euthanized 24 hr after infection to determine the number of neutrophils (<bold>B</bold>) and CFUs (<bold>C</bold>), and levels of TNF (<bold>D</bold>) and IL-17 (<bold>E</bold>) in BAL. Plasma levels of TNF (<bold>F</bold>), IL-17 (<bold>G</bold>), AST (<bold>H</bold>), ALT (<bold>I</bold>), ALP (<bold>J</bold>) and total bilirubin (<bold>K</bold>) were also evaluated 24 hr after infection. The amount of surface <italic>α</italic>2-3 sialic acids were assessed by MAL-II staining in SSC<sup>high</sup>/Gr-1<sup>high</sup> cells in BAL and analyzed by FACS, as shown by the representative histograms (<bold>L</bold>) and MFI (<bold>M</bold>); dotted line = unstained cells. The results are expressed as percent of survival, mean or median (only for FACS data) ± SEM. *<italic>P</italic> &lt; 0.05; *<italic>P</italic> &lt; 0.01; ***<italic>P</italic> &lt; 0.001. Sham = sham-operated mice; Osel = Oseltamivir; AST = alanine aminotransferase; ALT = aspartate aminotransferase; ALP = alkaline phosphatase.</p></caption><graphic xlink:href="EMS104139-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>High expression of NEU1 in cell types from COVID-19 patients.</title><p><bold>(A)</bold> Gene expression of NEU1, NEU3 and NEU4 across cell types in healthy donors and moderate or critical COVID-19 patients. Size of the circle is proportional to the percentage of cells expressing the reported genes at a normalized expression level higher than one. <bold>(B)</bold> UMAP analysis colored-coded by cell types in nasopharyngeal/pharyngeal swabs samples from healthy donors and COVID-19 patients. <bold>(C)</bold> Normalized expression of NEU1 overlaid on the UMAP spaces.</p></caption><graphic xlink:href="EMS104139-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Oseltamivir and Zanamivir decrease neutrophil activation and increase sialic acid levels in active, but not convalescent neutrophils from COVID-19 patients.</title><p>Whole blood from healthy donors (n= 10), severe COVID-19 patients (n= 6) or convalescent COVID-19 patients (n= 8) were treated or not with Oseltamivir (100 µM) or Zanamivir (30 µM) and total leukocytes were stained with the cell activation markers CD62L (<bold>A and E</bold>), CD66b (<bold>B and F</bold>) or the lectins MAL-II (<bold>C, D and G)</bold>, SNA (<bold>H</bold>) and PNA (<bold>I</bold>). Immunofluorescence (<bold>D)</bold> was carried out using biotinylated MAL-II followed by streptavidin Alexa Fluor 555 conjugate. Three different healthy donors (controls) and severe Covid-19 patients were used (magnification 100×). Blood samples from healthy donors (n = 7) were incubated for 2 h (37 °C, 5% CO<sub>2</sub>) with 7% of fresh plasma from healthy donors, severe or convalescent COVID-19 patients or with 7% of heat-inactivated plasma from severe COVID-19 patients in the presence or absence of Oseltamivir (100 µM) or Zanamivir (30 µM). Levels of CD66b (<bold>J</bold>), surface <italic>α</italic>2-3-Sia (MAL-II) (<bold>K</bold>), and ROS production (<bold>L, M</bold>) were assessed by FACS. The MFI was analyzed on CD66b<sup>+</sup>/CD15<sup>+</sup> cells using the gate strategies shown in <xref ref-type="supplementary-material" rid="SD2">Supplementary Fig. 1</xref>. Symbols represent individual donors and data are shown as scatter dot plot with line at median from pooled data of two to seven independent experiments. The statistical significance between the groups was assessed by ANOVA followed by a multiple comparisons test of Tukey. The accepted level of significance for the test was P&lt;0.05. * was significantly different when compared with Untreated Severe COVID-19; # was significantly different when compared with Untreated Heat-Inactivated Plasma from Severe COVID-19. Osel = Oseltamivir; Zana = Zanamivir.</p></caption><graphic xlink:href="EMS104139-f006"/></fig></floats-group></article>